The EEA1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the SK-HEP-1 line, offering a heterogeneous loss-of-function model for EEA1. The pool harbors diverse gene-disrupting mutations, eliminating EEA1 expression while preserving the native cellular context. This approach avoids clonal biases, providing a robust system for studying early endosomal biology.
The SK-HEP-1 host line originates from a liver adenocarcinoma patient’s ascites and is distinguished by its co-expression of epithelial and endothelial markers. This dual phenotype makes it a versatile tool for studying hepatocellular carcinoma progression and endothelial cell behavior, including angiogenesis and tumor?Cendothelial interactions. Its robust growth characteristics and compatibility with standard in vitro techniques facilitate reproducible endocytosis and migration assays.
EEA1 is a coiled-coil tethering factor essential for early endosome fusion. It binds Rab5-GTP and PI3P??generated by VPS34 kinase??on endosomal membranes, recruiting cofactors such as Rabaptin-5 and Rabenosyn-5 to facilitate SNARE-mediated fusion. This process controls endosomal maturation, sorting of cargoes like transferrin receptor back to the plasma membrane, and routing of activated EGFR for lysosomal degradation. Upstream signals including EGF and insulin converge on Rab5 and VPS34 to regulate EEA1 activity, tightly coupling growth factor signaling to endocytic trafficking.
In SK-HEP-1 cells, EEA1 knockout provides a powerful tool to dissect how endosomal dysfunction influences hepatocellular carcinoma and endothelial biology. Impaired early endosome fusion is predicted to alter integrin trafficking and growth factor receptor recycling, potentially reducing cell migration, invasion, and angiogenic mimicry??key malignant phenotypes. Additionally, disruption of endosomal entry pathways may reveal host factors critical for hepatotropic infections. Thus, this model bridges endosomal trafficking with cancer cell behavior and vascular pathology.
Applications include EGF and transferrin internalization assays to quantify endocytic activity, immunofluorescence for endosomal marker distribution, and live-cell imaging of endosome dynamics. Co-immunoprecipitation can confirm loss of EEA1?CRab5 binding, while Western blotting monitors downstream signaling changes. Functional assays such as wound healing and Transwell migration link EEA1-dependent trafficking to cell motility. These tools support research in drug delivery, receptor signaling, and endosomal diseases. For further information, contact Ascent Research.
